Hong Kong Industrialist Jan-Mar 2021

Judges’ Comments: •Willingness to take on challenges •Displayed insight in innovation & technology sector 評審委員會評語： •勇於接受挑戰  •擁有創新及科技方面的見解 2020 Mr Kingsley Leung Chairman, Uni-Bio Science Group 梁國龍先生 聯康生物科技集團  主席   A fter graduating from Imperial College and Oxford University with degrees in Biochemistry and Pharmacology, Mr Kingsley Leung started his career in various financial institutions and startup companies with a focus on healthcare- related investment and business development. This laid a strong foundation for him in building a career related to deep science, innovative business models and smart finance. Buoyed by this foundation, Mr Leung returned to his family business, Uni-Bio Science Group, in 2013 as the Head of Business Development, and kick started a new revolution for Uni-Bio Science, with a focus on forming strategic partnerships across the Group’s value chain. Examples include building a relationship with renowned industry leaders, such as China Resource in sales, Jiangsu Hansoh in R&D, and Sinopharm in manufacturing. After taking the helm as Chairman of Uni-Bio Science in 2017, Mr Leung has been dedicated to realising his vision of developing cutting-edge drugs with world-class science and technologies. Raising over RMB150M to embark on this vision, he started investing across the company value chain. On the R&D side, Mr Leung moved the Headquarters to Hong Kong Science Park, pioneered a new product development plan and steered the existing R&D platform towards a focus on new biologic formulation technology. On the manufacturing side, the Group put in place a new, state-of-the-art pre-filled sterile injection manufacturing line to support the commercialisation of two new osteoporosis and diabetes drugs. The Group has also moved the needle forward in sales & marketing by focusing more on expanding its direct sales channels, forming closer relationships with hospitals and establishing strategic partnerships with sector- specific distributors to enhance sales of core products. 2020 is yet another rollercoaster year. The COVID-19 outbreak has plunged the world’s economy into a full-stop, leaving a challenging environment to operate. To come up with a response plan, Mr Leung held consecutive emergency meetings with key management during Chinese New Year, a time when most provinces of China were in standstill. With the extra efforts of the Group’s own sales team, core product’s monthly turnover in May and June substantially outperformed the same period of last year, showing a strong V-curve market recovery. As an entrepreneur and financier, he understands the Group still faces many challenges before transforming to a strong, self-sufficient biopharmaceutical company, but his style is to tackle these challenges head-on. By collaborating with strategic partners, the Group will bridge various resources and pharmaceutical professionals to realise sustainable business growth. 梁 國龍在英國帝國理工學院和牛津大學獲得生物化學 和藥理學學位後，先後在多家金融機構和初創公司 從事與醫療相關的投資和業務發展工作，這為他在深度科 學、創新商業模式和智慧金融方面的職業發展奠定了基 礎。2013年，梁國龍回到家族企業聯康生物科技集團（聯 康生物）擔任業務發展主管，為集團與業內著名的龍頭企 業建立策略性合作夥伴關係。例如，與華潤集團建立銷售 領域合作、與江蘇豪森集團建立研發領域合作和與國藥集 團建立製造領域合作。 於2017年出任聯康生物科技集團主席後，梁國龍一直 致力透過世界一流的科學和技術，研發尖端藥物。為了實 現這願景，他籌集了逾1億5千萬元人民幣，開始在公司 價值鏈的各個環節進行投資。在研發方面，梁國龍將公司 總部遷至香港科學園，並率先推行新產品開發計畫，帶領 現有的研發平台專注於新的生物製劑技術。在生產方面， 該集團建立了一條全新和最先進的預填充無菌注射生產 線，以支持兩種新的骨質疏鬆和糖尿病藥物的商業化。集 團在銷售和營銷方面也取得了顯著進展，更關注拓展直銷 渠道，與醫院建立更密切的關係，並與特定行業的分銷商 建立策略夥伴關係，以提高核心產品的銷售。2019年底， 集團銷售額突破2億元。 2020年是跌宕起伏的一年。新冠肺炎疫情使世界經濟 全面停頓，為商業環境帶來挑戰。為了制定應對方案，梁 國龍在農曆新年期間不斷與管理層召開緊急會議，當時中 國大部分地區都處於停滯狀態。在集團銷售團隊的努力下， 5至6月份核心產品的每月營業額明顯勝於去年同期，呈 現強勁的V型復甦曲線。作為一名企業家和金融家，梁國 龍明白，集團在轉型為一家強大、自給自足的生物製藥公 司之前，仍面臨許多挑戰，但他的風格是正面面對這些挑 戰。通過與策略夥伴的合作，集團將在各種資源和醫藥專 業人員之間築起橋樑，實現業務的持續增長。 Nominator: Mr Tony Yau Chief Executive Officer & Director of HeungKong Financial Group 提名人：邱國榮先生 香江金融集團有限公司　首席執行官及董事 1-3/2021 | 75